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ABSTRACT 
Introduction: Nitric oxide (NO) has been shown to possess anti-inflammatory 
properties. In a porcine endotoxin model the combination of intravenously (iv) 
administrated glucocorticoid (gc) and inhaled NO (iNO) compared to gc or iNO given 
separately, blunted the inflammatory response in vital organs. The ischemia and 
reperfusion (I/R) syndrome has an essential role regarding the pathogenesis in a number 
of clinical conditions. Animal and human studies have shown favourable effects with 
exogenously administrated NO in different I/R models.  
Aim: The overall aim of this thesis was to study the potential of inhaled NO as a 
modulator of the inflammatory response in humans. In study I-III two different 
concentration of iNO in combination with gc was studied and evaluated using clinical 
parameters and cytokines in plasma (study I-II) as well as microparticles in plasma 
(study III). In study IV we evaluated whether knee surgery in spinal anesthesia during 
tourniquet could be used as a model to study I/R, and if so, if this could be attenuated 
by iNO.  
Methods: In study I-III an endotoxin model was employed in 30 healthy human 
volunteers participating in 60 experiments. Study III is based on samples taken 
separately in study II. The studies were double-blind, cross-over and randomised with 
regard to iNO and placebo (nitrogen, N2), i.e. every volunteer had iv endotoxin (2 
ng/kg) and iv gc (2 mg/kg) combined with iNO in one experiment (iNO/gc) and with 
placebo (placebo/gc) in the other. In study I endotoxin was given before gc and iNO 
(30 ppm lasting for 5 hours), while in study II iNO (80 ppm, lasting for 7.5 hours) was 
initiated first, followed by endotoxin and gc. Clinical symptoms were recorded and 
blood samples collected. In study IV patients consecutively submitted to knee 
arthroplasty in spinal anaesthesia were included. As a standard procedure a tourniquet 
was used to create a bloodless surgical field. The patients were randomised into three 
groups (n=15). Groups 1 and 3 were either receiving iNO 80 ppm or placebo 
throughout the entire operation, whereas group 2 received iNO 80 ppm just in the 
beginning and in the end of the operation, hence, no iNO during the period with 
activated tourniquet. Blood samples and muscle biopsies were collected during the 
operation. Adhesion molecules before and after the ischemic period were analysed. 
Results: In study I and II endotoxin elicited typical flulike symptoms e.g. headache and 
fever as well as activation of cytokine levels. In study III there was an increase in 
platelet and monocyte microparticles (MP) while endothelial derived MP were 
unaltered. Also, platelet derived MP positive to CD40L and monocyte MP positive to 
HMGB1 showed an early increase. There was no difference between the two 
treatments (iNO/gc and placebo/gc) in study I-III. In study IV no signs of endothelial 
cell activation or inflammatory response neither systemically nor locally in adjacent 
muscle were seen. 
Conclusions: The present human endotoxaemic model exhibited reproducible results, 
thereby providing a stable and safe model for randomized studies. The combination of 
intravenously administered gc and iNO, elicited no anti-inflammatory effect. The 
endotoxin infusion in healthy volunteers resulted in an increase in plasma cytokines as 
well as in microparticles released from platelets and from monocytes but not from the 
endothelium. In patients undergoing knee arthroplasty in spinal anesthesia, the 
ischemia/reperfusion created by a tourniquet did not cause any signs of endothelial cell 
activation or inflammatory response.   
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The inflammatory reaction involves a response that is the coordinated reaction of the 
immune system; a collection of cells, tissues and molecules mediating resistance to 
infections. Inflammation is initiated by a plurality of elements including infections with 
pathogens or their products (e.g. endotoxins/lipopolysaccharides), tissue damage with 
following cell injury, as well as episodes with reperfusion after ischemic events. At the 
site of injury, the inflammatory response causes activation and accumulation of 
leukocytes and plasma proteins. The inflammation per se may cause tissue damage (1). 
 
THE IMMUNE SYSTEM 
Protection of the host is the primary physiological role of the immune system. The 
immune system is classically divided into the innate immunity that mediates the initial 
inflammatory response and the adaptive immunity which is the more specific and 
powerful response system and also a more slowly activated part of the immune system 
(1).  
The innate immunity is always present and prepared to rapidly eliminate microbes. It 
consists of phagocytes (macrophages and neutrophils that ingest and destroy microbes), 
natural killer (NK) cells that recognize and kill infected cells, and also dendritic cells 
that together with macrophages serve as antigen-presenting cells which stimulate the 
subsequent adaptive immunity. In the innate immune system all the cells of a particular 
type, e.g. macrophages, have identical receptors on their surface. Hence, many cells are 
able to recognise the same microbe (1). 
Adaptive immune responses develop later in life compared to the innate immunity 
system. The adaptive immunity is based on antigen-specific cells in contrast to the 
innate immunity. The adaptive immunity is in itself divided in two groups; humoral and 
cell-mediated immunity. Humoral immunity is mediated via B lymphocytes producing 
and secreting antibodies in order to neutralise and eliminate microbes and microbial 
toxins present outside the host cells. The cell-mediated immunity is represented by T 
lymphocytes defending against microbes that living and dividing inside the infected 
cells, thereby inaccessible to antibodies, T lymphocytes recognise antigen fragments 
displayed on the surface of the infected cells.  
The adaptive immunity response often enhances the antimicrobial mechanism of the 
innate immunity, e.g. by antibodies binding to microbes thereby activating phagocytes, 
and T lymphocytes (helper T cells) producing cytokines that activate phagocytes (as 
well as T- and B- lymphocytes). Another feature of the adaptive immune system is the 




EARLY INFLAMMATORY RESPONSE 
Phagocytes (neutrophils, monocytes) are among the first cells responding to an 
inflammatory stimulus, infection or trauma. Phagocytes are recruited from the 
bloodstream to the site of the initial inflammatory insult in response to chemotactic 
stimuli (i.e. chemokines, chemoattractant cytokines e.g. IL-8) (2). Monocytes mature 
into macrophages as they enter non-vascular tissue. At the site of the insult tissue 
macrophages and dendritic cells produce cytokines (e.g. TNF and IL-1 and 
chemokines) that activate the endothelium. This activation leads to the production of 
adhesion molecules and cytokines, the latter causing further activation of leukocytes 
and monocytes. The neutrophils and monocytes have to migrate through the vessel wall 
in order to reach the site of inflammation, this requires adhesion molecules expressed 
on the activated endothelium and leukocytes/monocytes.  
Neutrophils and macrophages recruited to the site of infection ingest and destroy 
microbes by means of nitric oxide (NO, produced by inducible nitric oxide synthetase, 
iNOS), reactive oxygen species (ROS) and enzymes, these products may be liberated 
extracellulary and thereby contribute to the inflammatory reaction and tissue damage 
(1, 3, 4).  
 
INTERACTION BETWEEN ENDOTHELIAL CELLS AND LEUKOCYTES  
Adhesion molecules are of great importance in the inflammatory host response as they 
mediate the interaction between leukocytes and endothelial cells. The interaction 
involves three stages; rolling (low affinity interaction), firm adhesion and 
transendothelial migration (3) (Fig. 1).  
During the leukocyte rolling the adhesion molecules E- and P-selectin on the 
endothelium interact with corresponding ligands on leukocytes (e.g L-selectin). 
Integrins (CD11a/CD18 and CD11b/CD18) are glycoproteins expressed on the surface 
of leukocytes, function as ligands interacting with ICAM (intercellular adhesion 
molecule) and VCAM (vascular adhesion molecule) expressed on the endothelium to 
enable firm adhesion, and finally the interaction between PECAM-1 (platelet-
Figure 1. Three stages of leukocytes interaction with the endothelium in response to 
activation. 
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endothelial cell adhesion molecule) expressed both on the endothelium and on 
leukocytes enable the migration through the vessel wall (3, 5, 6). The major site of 
adhesion (rolling) is the postcapillary venule where the interaction between leukocytes 
and endothelium occur, all dependent on adhesion molecules (3). Monocytes and 
activated T lymphocytes are believed to follow the same mechanisms in order to reach 
the site of infection/inflammation (1, 3).  
ICAM and VCAM are constitutively expressed on the endothelial cell surface, and 
may, after inflammatory stimuli, be further induced leading to enhanced amounts (7, 8). 
P-selectin is found in storage granules (Weibel-Palade bodies) in the endothelia cells as 
well as in platelets (alpha granules) and is rapidly mobilized, within minutes, to the cell 
surface upon inflammatory stimulation (5). E-selectin expression is under 
transcriptional control and may be induced by cytokines such as TNF and IL-1 and is 
therefore not as rapidly expressed as P-selectin in response to inflammatory stimulation 
(3). Soluble forms of adhesion molecules are detectable in biological fluids and their 
concentrations may reflect an increased expression on cellular level due to an 
inflammatory response (6, 9). 
 
CYTOKINES 
The first proposal that soluble factors may influence inflammatory reactions was made 
in 1944 when Menkin “purified” fever generating properties from inflammatory 
exudates and named these factors “pyrexins”. In 1953 Bennett and Beeson were able to 
show that in acute inflammatory exudates endogenous pyrogens could be separated 
from bacterial pyrogens (endotoxins). They also managed to extract endogenous 
pyrogens from leukocytes in peripheral blood. In 1974 the term “cytokines” was 
proposed for the family of proteins produced and secreted by different cell types 
promoting the immunologically mediated inflammatory reactions. Today most 
cytokines are called interleukins (IL) because they are molecules produced by 
leukocytes and acting on leukocytes. However, this is a far too limited definition since 
many cytokines/interleukins are produced by, and act on, other cells than leukocytes (1, 
10). 
Cytokines are soluble proteins functioning as molecular messengers between cells, they 
interact with the immune system in order to regulate various inflammatory responses as 
well as having an impact on cell growth, differentiation and development (10). The 
cytokines interact with target cells via high-affinity receptors, these receptors may be 
located on the cell producing the cytokine (autocrine action), on adjacent cells 
(paracrine action) or even distributed to distant target cells (endocrine action) (1, 10, 
11).  
In the immune system many cytokines promote the inflammatory reactions, so called 
pro-inflammatory. There are also cytokines that function mainly as down-regulators of 
the inflammatory response, e.g. transforming growth factor B (TGFβ) and IL-10. Some 
microbes have “taken advantage” of the down-regulating mechanisms, an example 
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being the Epstein Barr Virus (EBV) producing a “virokine” version of IL-10, resulting 
in a suppression of the host resistance (10).  
Macrophages and dendritic cells are the major origin of cytokines in the innate immune 
system while T cells are the main source in the adaptive immune system (1). 
 
HIGH MOBILITY GROUP BOX PROTEIN 1 (HMGB1) AND ITS RECEPTORS  
 
HMGB1 
Previously, HMGB1 was known as a protein existing in profuse amounts in the 
cytoplasm and in the nucleus of most cells, being a nuclear component interacting with 
DNA to modify its structure and regulate gene expression (12). It is a highly conserved 
protein with a 99% identical amino acid sequence homology in mammals (13). In 1999 
HMGB1 was revealed as an important late mediator of sepsis in an endotoxin model on 
mice. It was shown that antibodies to HMGB1 decreased endotoxin induced lethality 
and that administration of HMGB1 in itself was lethal. Also, in septic patients, an 
elevated level of HMGB1 in serum was correlated with outcome (survivors/non-
survivors) (14).  
In response to proinflammatory stimuli (e.g. LPS, TNFα and IL-1β) HMGB1 
translocates to the cytoplasm and is released extracellulary by activated 
monocytes/macrophages, thus acting as a cytokine (15). It has been shown that 
HMGB1 is passively released from necrotic or damaged, but not apoptotic cells, due to 
the tight bonding of HMGB1 to chromatin (the combination of DNA and proteins in 
the nucleus) (13, 16). However, in recent years, observations have indicated a 
relationship between apoptosis and the release of HMGB1 (17, 18). Dying/apoptotic 
cells produce ROS in mitochondria leading to the oxidation of HMGB1. The 
importance of the HMGB1 redox status as a generator of inflammation cannot be 
underestimated since it has been elicited to inhibit the inflammatory response (19). On 
the other hand, the reduced form of HMGB1 activates inflammatory cells (19, 20).  
Due to its immunological properties HMGB1 released from damaged tissue can be 
designated as an alarmin or DAMP (damage or death-associated molecular pattern), a 
signal of traumatic cell death (13, 18). The release of HMGB1 promotes signals that 
lead to both a pro-inflammatory response as well as tissue regeneration (13, 18). The 
passive release of HMGB1 from necrotic/damaged cells is believed to occur early, in 
contrast to the active secretion that occurs later. Consequently, HMGB1 has been 
designated to serve as a late mediator of sepsis, but as an early mediator of tissue 
damage e.g. in ischemia reperfusion (I/R) injury (12, 14, 21). In mice, an increased 
level of HMGB1 has been seen 8-32 hours after endotoxin challenge and 18 hours after 
surgical induction of peritonitis (14, 22).  
It has been shown that HMGB1 is of vital importance in mediating injury in I/R. 
HMGB1 protein expression in the liver was up-regulated one hour after reperfusion and 
in cerebral ischemia 4 hours after start of the ischemic event, also, after 30 minutes in 
the heart, all in murine experiments (21, 23, 24). In patient studies with cerebral and 
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myocardial ischemia respectively, elevated levels of HMGB1 were seen within 24 
hours (24, 25). HMGB1 has been demonstrated to interact mainly through receptor of 
advanced glycation end products (RAGE) (23, 24) and Toll-like receptor 4 (TLR4) (21, 
26) but also via other receptors in the TLR family (27). 
Apart from inducing cytokine secretion HMGB1 facilitates the inflammatory response 
by activating the endothelial production of adhesion molecules, also, interaction with 
RAGE results in migration of monocytes (28, 29). 
 
Receptor of advanced glycation end products (RAGE) 
RAGE is a transmembrane multiligand receptor, binding to a variety of ligands such as 
HMGB1 and advanced glycation end products (AGE) (30). AGE are macromolecules 
such as proteins, lipids and nucleic acids formed by glycation. The production of AGE 
is higher in pro-oxidant environment and in diabetics due to the altered glucose 
metabolism (31). The interaction of RAGE with HMGB1 mediates cytokine production 
in monocytes and neutrophils by activating several intracellular signal pathways 
including the nuclear factor-ҚB (NF- ҚB) and mitogen-activated protein kinases 
(MAPK) (30, 32). 
Soluble RAGE (sRAGE), a truncated non cell bound isoform of RAGE circulates in 
plasma functioning as a “decoy” and may thereby prevent activation of the cell surface 
receptor (30). The levels of sRAGE have been shown to be elevated and associated 
with outcome in septic patients (33). In patients with higher baseline sRAGE an 
association with increased severity of acute lung injury and increased mortality has 
been seen (34). Also, in a model with human volunteers given a moderate dose of 
endotoxin a significant increase in sRAGE was demonstrated (35).  
 
ENDOTOXIN CHALLENGE AS A MODEL FOR INFLAMMATION  
Sepsis and the systemic inflammatory response syndrome (SIRS) is a result of failure in 
the host infection control mechanisms and is often initiated by bacterial 
lipopolysaccharide (LPS/endotoxin) (36). In USA more than 750 000 cases of severe 
sepsis are estimated to occur every year with an in-hospital mortality of 29 to 50% or 
even higher if the patients develop septic shock (hypotension not responding to fluid 
resuscitation) (37). The mechanism underlying endotoxin shock was described by 
Hinshaw in 1956-58, but the role of bacterial toxins was described as early as 1888 by 
Roux and Yersin (36). 
Endotoxin / bacterial lipopolysaccharide (LPS) is found in the outer membrane of 
various Gram-negative bacteria. It consists of a hydrophilic polysaccharide (sugar) 
chain on the surface of the bacterial cells and a hydrophobic lipid moiety known as 
lipid A that is located in the outer leaflet of the outer cell membrane, the latter 
responsible for the toxic effects. The LPS structure may differ between different 
bacteria. The shifts in structures are not necessary for the survival of the bacteria, but 
have implications regarding its virulence (38).  
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LPS is one of the most forceful pro-inflammatory agonist for human leukocytes (39). 
LPS interacts with TLR4, facilitated by CD14 and lipopolysaccharide-binding protein 
(LBP) (38). This interaction activates nuclear factor kappa B (NF-ҚB), a so called 
stress-responsive transcription factor that regulates the gene expression of different 
cytokines. The activation results in the synthesis and release of various cytokines 
considered characteristic in sepsis and the systemic inflammatory response syndrome 
(SIRS). NF-ҚB may also be induced by cytokines through their respective receptors on 
the cell membrane (4). 
The use of endotoxin challenge in human volunteers in order to induce a systemic 
inflammatory reaction has been proved to be a safe, reliable and reproducible method 
(40). The model has been used for several years in order to study physiological 
reactions such as cardiovascular parameters and cytokine release, but also potential 




These proteins can be produced inside both gram-positive and gram-negative bacteria. 
Once outside the bacteria the exotoxin may function as cytolytic enzymes causing 
membrane disruption, or as receptor binding proteins that alter the function of or kill 
the cell. 
Due to the receptor binding, many exotoxins from pathogens such as Vibrio cholera or 




Glucocorticoids are a class of steroid hormones built from the lipophilic cholesterol 
skeleton. Hence, they penetrate easily the cell membrane and reach all tissues including 
the brain (46). The glucocorticoid receptor (GR) complex is found in the cytoplasm of 
cells. After interaction between glucocorticoid and GR the complex is translocated into 
the nucleus where the GR complex interacts with target genes and transcriptions factors 
such as NF-ҚB, in order to enhance or repress transcription. The major anti-
inflammatory and immunosuppressive effect of glucocorticoids is considered to be the 
inhibition of pro-inflammatory cytokines and the increase of anti-inflammatory protein 
production like IL-1ra (47, 48).  
 
NITRIC OXIDE 
In 1980 endothelium dependent relaxation was first described by Furchgott and 
Zawadzki, who found that the relaxation on isolated blood vessels by acetylcholine 
required the presence of endothelial cells (49). Further studies revealed that stimulated 
endothelial cells did release a factor that diffused to the smooth muscle cells where it 
caused relaxation, endothelial-derived relaxing factor (50). This substance with 
vasodilatation properties was in 1987 proposed to be nitric oxide (NO) (51). NO 
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consists of one nitrogen atom covalently bound to an oxygen atom with one 
unpaired/free electron, this makes the molecule a highly reactive free radical (52). 
Continued studies have revealed NO as a molecule with many important features in 
addition to vasoregulation. NO has been shown to possess anti-inflammatory properties 
by limiting platelet activation/aggregation as well as leukocyte adhesion to the 
endothelium (53, 54). Also, NO reduces the production of proinflammatory cytokines 
in the human endothelium (53), macrophages (55) and neutrophils (56) as well as 
regulating (reduction) myocardial contractility (54). Further, NO has been revealed to 
function as a signalling molecule in both the central and the peripheral nervous system, 
and when produced by macrophages and neutrophils, a defending mechanism against 
microbes (54, 57). In 1992 NO was declared “molecule of the year” by Science 
Magazine due to its properties as an important messenger molecule and part of the 
immune defence (58). Robert Furchgott, Louis Ignarro and Ferid Murad received the 
Nobel Prize in 1998 for their discoveries concerning "the nitric oxide as a signalling 
molecule in the cardiovascular system" (www.nobelprize.org) (51, 58).  
Endogenous NO is synthesized by a family of NO synthases (NOS) catalysing the 
conversion of L-arginine to the free radical NO and L-citrulline. There are three 
isoforms of NO synthase, initially named after the tissues they first were identified in; 
neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The 
latter is expressed in several cell types including macrophages and neutrophils in 
response to inflammatory stimulus (51, 59). From endothelial cells NO diffuses, 
catalyzed by eNOS, to the smooth muscle cells as it is highly lipid soluble and 
membrane permeable (60). In the smooth muscle cells NO activates soluble guanylate 
cyclase causing vasodilatation via the synthesis of cyclic GMP from GTP (51, 61). 
When the combination of iNO and intravenous glucocorticoids was used as a treatment 
after endotoxin challenge in a porcine model lasting for 6 hours, the inflammatory 
response in systemic organs was blunted compared to treatment with iNO or 
glucocorticoids separately (62). In this porcine model endotoxin infusion decreased 
glucocorticoid receptor (GR) expression in lung, liver and kidney tissue. iNO was 
considered to induce an upregulation in GR expression and it was suggested that this 
GR upregulation made glucocorticoids more effective (62). 
 
NITRIC OXIDE AND ISCHEMIA REPERFUSION INJURY 
The ischemia and reperfusion (I/R) syndrome has an essential role regarding the 
pathogenesis in a number of clinical conditions such as stroke, myocardial infarction 
and organ transplantation (63-65). Reperfusion, necessary in providing the post-
ischemic tissue with oxygen and other metabolic substrates after ischemia results in 
acceleration of the cellular necrotic process and may cause the same consequences as 
prolonged ischemia (63, 66). The formation of reactive oxygen species (ROS, e.g. 
superoxide, O2-, or hydrogen peroxide, H2O2) contributes to the expression of several 
different adhesion molecules on leukocytes and vascular endothelia in combination 
with reduced amounts of the antiadhesive NO (66, 67). As a result, neutrophils 
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emigrate to the extravascular compartment causing microvascular barrier disruption 
and edema (66, 68). ROS also stimulates cytokine and chemokine production through 
NF-ҚB activation (69). NO has been demonstrated to affect the adherence of 
leukocytes and platelets to the endothelium by downregulating the expression of the 
adhesion molecules (ICAM, VCAM, P-selectin) (53, 67, 70, 71). The leukocyte 
adherence to the endothelium results in capillary plugging and edema formation which 
causes the “no-reflow” phenomenon characterising the I/R injury (72). The balance 
between ROS and NO seems to be an important factor regarding the leukocyte and 
platelet adhesion induced by I/R. During oxidative stress, (imbalance between 
production of oxidizing species and capability of antioxidant defence) as in the case of 
I/R, eNOS may generate superoxide (O2-) (73, 74). Together O2- and NO form the 
highly reactive free radical peroxynitrite (OONO-), a potent inducer of cell death and a 
substance that has been suggested contributing to the I/R injury (73, 75). However, 
there are facts indicating that the interaction between NO and O2- creating OONO- 
could be beneficial since OONO- possibly acts as a O2- radical scavenger. The ratio 
O2−/NO would therefore be of importance during I/R in terms of antioxidation (76). 
Other suggested mechanisms for NO in protecting organs against I/R injury are 
illustrated in Fig. 2 and include; reduction of pro-inflammatory cytokines (e.g. TNF-α 
and IL-1β) and enhanced levels of anti-inflammatory cytokines (e.g. IL-10) (53, 77), 
decreased production of chemokines (macrophage inflammatory proteins, MIP-1 and 
Figure 2. A summary of some possible mechanistic effects by exogenous NO during I/R. 
Decreased apoptosis and neutrophil infiltration help to protect the cell during ischemia and 
reperfusion and contribute to diminished organ injury.  
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MIP-2) (78), inhibit NF-ҚB activation (79) and activator protein 1 (AP-1) dependent 
apoptosis (programmed cell death) (80), inhibit apoptosis by downregulation of gene 
p53 (81).  
 
The half-life of NO in whole blood is very short (< 2 ms) due to the fast oxidation of 
oxygenated haemoglobin where methaemoglobin and nitrate (NO3-) are produced, and 
the oxidation of NO in plasma where nitrite (NO2-) is formed (Fig. 3) (82, 83). Thus, 
nitrate and nitrite are oxidative breakdown products of NO long considered as inert 
metabolites with limited intrinsic biological activity (84). 
Furthermore, nitrite can be reduced to NO by deoxy-haemoglobin where 
methaemoglobin once again is created. The balance of oxy-haemoglobin/deoxy-
haemoglobin affects the vascular tone and blood flow by inactivation or production of 
NO (83). However, there are also other reductases that can generate NO from nitrite 
under anaerobic conditions like deoxymyoglobin (85) and xanthine oxidase (86). 
Hence, NO produced by nitric oxide synthases (NOS) during normoxia serves as an 
“ischemic NO buffer” being stored mostly in erythrocytes as nitrite (87), then 
regenerating to NO during hypoxia and ischemia when the NOS function is limited due 
to lack of the substrate oxygen (88, 89) and decreased eNOS protein (59). This down-
regulation or altered function of endothelial/constitutive NOS (eNOS) seems to be of 
great significance for the cytoprotection in the I/R scenery (72, 74).  
NO administered exogenously (inhaled) has been shown to exert anti-inflammatory 
properties in I/R settings, both in animal (90-92) and in human (93, 94) studies. In 
patients, the inflammatory response was attenuated by iNO in a setting where the 
patients, in general anaesthesia, had knee surgery with a bloodless technique using a 
Figure 3. NO synthesized by eNOS in the endothelial cells is in the bloodstream partly 
converted by plasma ceruloplasmin (Cp) to NO2- which serves as a stable reservoir, later 
capable of reacting with oxy-Hb or deoxy-Hb generating NO3- or NO. Cp = ceruloplasmin, 
NO3- = nitrate, NO2- = nitrite.  
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tourniquet (93). In analogy with these findings, an endocrine role of NO has been 
demonstrated since endogenously derived NO is transported in the blood and 
metabolised into remote organs, where it mediates cytoprotection in an animal setting 
of I/R injury (95). 
 
CELLULAR MICROPARTICLES (MP) 
MPs were called “platelet-dust” promoting coagulation when first described in 1967 
(96). MPs are fragments shed from the plasma membrane of different cell types such as 
leukocytes, platelets and endothelial cells during activation or apoptosis (97, 98). They 
are identified using flow cytometry. Approximately 70-90% of microparticles in the 
blood stream emanate from platelets (99). MPs have different sizes (0.1-1 µm) and 
composition in proteins and lipids, they also carry different membrane antigens and 
procoagulant entities such as tissue factor depending on the cell origin (97, 100, 101). 
MPs are prothrombotic since they have an over-representation of negatively charged 
phosphatidylserine (PS) on the outer surface, effectively binding coagulation factors 
(102). 
Since MPs carry antigens and receptors from their cell of origin, they can transfer these 
surface signalling molecules to other cells of different origin, initiating intracellular 
pathways (102, 103). As well as having pro-coagulant properties, MPs may also 
directly affect endothelial and monocytic functions contributing to the inflammatory 
process (104). The suspected involvement of MPs in clinical disease was demonstrated 
for the first time in 1989 in patients having the rare congenital bleeding disorder called 
Scott syndrome, it was found that platelets were impaired in their capacity to produce 
MPs (105). Subsequently, in 1992 it was demonstrated and confirmed that patients with 
idiopathic thrombocytopenic purpura (ITP), despite low platelet count had elevated 
levels of platelet derived MPs protecting them from bleeding (106). Increased levels of 
MPs have been observed in conditions such as diabetes, hypertension, stroke, acute 
coronary syndromes and hypertriglyceridemia (107). Therefore, MPs may be 
considered markers of cardiovascular risk (102, 108). Elevated levels have also been 
found in disseminated intravascular coagulation (DIC)/meningococcal sepsis and are 
associated with enhanced coagulation (100). 
 
CLINICAL IMPLICATIONS 
As mentioned above, sepsis and SIRS, the result of inability in the host infection 
control, are common and sometimes fatal conditions (37). Also, the I/R injury has an 
essential role in a number of severe clinical conditions (63, 64).  
To study immunomodulation in a human experimental setup as well as in a patient 
model may provide an increased understanding in the complex mechanisms of 
inflammation.  
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AIMS 
The overall aim of this thesis was to investigate the potential role of inhaled nitric oxide 
(iNO) as a modulator of inflammation in humans. 
 
More specifically, the studies aimed to: 
 
• Study the potential anti-inflammatory effect of two different concentrations (30 
and 80 ppm) iNO in combination with hydrocortisone (2 mg/kg) in a human 
endotoxin model as assessed by; 
1. Clinical parameters 
2. Cytokines in plasma  
3. Microparticles in plasma 
 
• Study if the surgical technique performed by tourniquet ischemia in knee 
surgery with regional anaesthesia is a relevant model for activation of 
ischemia/reperfusion inflammatory response. 
 
• Study if the inflammatory response, provoked by surgical tourniquet ischemia, 





SUBJECTS AND METHODS  
ETHICAL CONSIDERATIONS 
The protocols for study I-IV were approved by the Human Research Ethics Committee 
at Karolinska Institutet, Stockholm. The protocols were also approved by the Swedish 
Medical Product Agency. 
The site of the studies was at the department of anaesthesia and intensive care 
medicine, Karolinska University Hospital, Huddinge, Stockholm. 
The volunteers were, before admittance to the study, asked their health state and had a 
physical and laboratory examination. Written informed consent was obtained from the 
volunteers as well as from the patients before each study.  
 
EXPERIMENTAL PROTOCOL STUDY I, II AND III 
A total of 30 healthy volunteers were investigated in 60 experiments, study III is based 
on samples taken separately in conjunction with the implementation of study II. Fifteen 
Figure 4. Flow diagram of the design; human volunteers in a cross-over design receiving 
endotoxin and glucocorticoids (gc) both times, iNO (inhaled nitric oxide) or placebo 
(inhaled N2) was randomised. Wash out period of 4 and 6 weeks or more in study I and 
II respectively.  
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different volunteers were investigated twice in each of the studies I and II. Age range 
was 19-32 years and they all had normal BMI (range, 18-29), there were 21 men and 9 
women. 
Intravenous administration of endotoxin and hydrocortisone was given in all of these 
experiments, while the administration of inhaled nitric oxide (iNO) or placebo 
(nitrogen, N2) was randomised and given in a double-blind crossover fashion (Fig. 4). 
At least 4 weeks elapsed between the experiments as a wash out period. The volunteers 
all arrived in the morning after having had a light breakfast, they were thereafter put 
into bed and randomisation took place. Two intravenous lines were inserted, 18 gauge 
in the cubital fossa for blood sampling, and 20 gauge for infusions (BD Venflon™) in 
the opposite arm. After a 30 min rest, baseline blood samples were harvested. 
Tympanic temperature (ThermoScan pro 1, Thermoscan Inc. San Diego, USA), 
respiratory rate, peripheral oxygen saturation (SpO2), pulse, ECG monitoring, non-
invasive blood pressure (Datex Engström Light®, Helsinki, Finland) were registered. 
Temperature, respiratory rate, and non-invasive blood pressure were measured every 30 
minutes. SpO2, heart rate and ECG were measured continuously. Nitrogen dioxide 
(NO2) was constantly measured (INOvent®) in inspired air as recommended by the 
manufacturer. Visual Analog Scale (VAS) was used for assessment of nausea, 
headache and low back pain every 30 minutes throughout the experiment. 
 
SPECIFIC PROTOCOL STUDY I 
After baseline samples (at time –0.5 h), endotoxin was infused during 5 minutes (Fig. 
5). Infusion with Ringers Acetate started in parallel with the endotoxin injection. 
Hydrocortisone was injected 30 minutes after the endotoxin infusion. Thereafter, at 
time 0 h, treatment with NO (30 ppm) inhalation (iNO) or placebo gas lasting for 5 
hours was initiated. The gas was mixed and administered through a nasal cannula 
Figure 5. Flow chart of the design in study I. 
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(SALTER LABS, California, USA). Blood samples were collected at -0.5 hours and at 
1, 2, 3, 5 hours. 
 
SPECIFIC PROTOCOL STUDY II AND III 
After baseline samples (–2.5 h), treatment with iNO (80 ppm) or placebo gas lasting for 
7.5 hours was initiated (Fig. 6).  
The gas was mixed and administered through a nasal cannula (SALTER LABS, 
California, USA). Two hours after the initiation iNO or placebo inhalation, endotoxin 
was infused during 5 minutes (at time -0.5 h). Infusion with Ringer’s Acetate started in 
parallel with the endotoxin infusion. Hydrocortisone was injected intravenously 30 
minutes after the endotoxin injection (at time 0 h). Blood samples were collected at -2.5 
hours and at -0.5, 1, 2, 3, 5, 8 as well as 24 hours (every hour in order to measure 
methaemoglobin). 
 
REAGENTS AND TREATMENTS STUDY I, II AND III 
Endotoxin (2 ng/kg BW, Lot nr G3E069, United States Pharmacopeia, Rockville, 
USA) was mixed with sterile water and treated for 10 minutes by ultrasound (Bransonic 
3510, Bransonic Ultrasonic Corp, Danbury, USA) before administration in order to 
avoid flocculation. Endotoxin was infused during 5 minutes followed by a flush of 20 
ml saline.  
Infusion with Ringer’s Acetate (Baxter Viaflo, Kista, Sweden) 2 ml/kg BW per hour 
and hydrocortisone sodium succinate (2 mg/kg BW, Solu-Cortef ®, Pfizer, Sweden) 
was used. NO (final blended at a concentration of 30 and 80 ppm NO respectively in 
inspired gas, INOmax®, INO Therapeutics, 1060 Allendale Dr. Port Allen, LA 70767, 
USA) in an oxygen flow of 3 L per minute or placebo (nitrogen, N2, INO Therapeutics) 
was administered through the INOvent® delivery system, Datex Ohmeda , Inc. 
Madison, USA. 
 
Figure 6. Flow chart of the design in study II. 
   19 
BLOOD SAMPLING STUDY I AND II  
Blood samples were collected (without a tourniquet) into test tubes containing EDTA. 
Plasma was collected after centrifugation at 4,000 rpm for 10 min in +4◦C and then 
frozen at –80°C until subsequent analysis. Hematological parameters (white blood cell 
count, platelet count and haemoglobin) were analyzed within 5 hours at the accredited 
hospital laboratory. Venous blood samples for methaemoglobin, were measured with 
ABL800 Flex blood gas instrument (Radiometer Medical, Brønshøj, Denmark). 
In study I plasma levels of cytokines IL-1beta, IL-1ra, IL-6, IL-10, TNFα, 
(Biosource™, Belgium) and RAGE (R&D systems®, Abingdon, UK) were measured 
using commercially available ELISA kits according to manufacturer’s instructions.  
In study II plasma levels of cytokines IFN – γ, IL-1beta, IL- 2, 4 5, 8, 10, 12, 13 and 
TNFα, were measured with an electrochemiluminescence technique (MSD®, 
Gaithersburg, Maryland, USA). This method allows a small sample volume (25 µ-liters 
per well) to be used in a multiplex format for several cytokines. ELISA assay kits were 
used according to the manufacturer’s instructions for analysing IL-6 and sRAGE (R&D 
systems®, Abingdon, UK) and HMGB1 (Shino-Test Corporation, Japan). The latter 
three were measured at -2,5 hours and at -0,5, 1, 3 and 24 hours. 
 
BLOOD SAMPLING STUDY III 
Blood samples were collected (without a tourniquet, in conjunction with study II) at -
2.5 hours and at -0.5, 2, 5, as well as 24 hours into test tubes containing 1/10 0.129 M 
sodium citrate (Fig. 6). Plasma was collected after centrifugation at 4,000 rpm for 10 
minutes in +4◦C and then frozen at –80°C until subsequent analysis using flow 
cytometry. The protocol regarding analysis of microparticles is thoroughly described in 
paper IV. Basically, flow cytometry works using a laserbeam illuminate particles 
passing in a stream. Since the laser light is scattered by the particles, this scattered light 
can be used to count and measure the size of the particles. Epitopes can be identified by 
using an antibody linked to a fluorescent dye. The laser light excites the dye that emits 
a colour of light that is detected. A computer collects the information from both the 
scattered and the fluorescence lights (109).  
 
EXPERIMENTAL PROTOCOL STUDY IV 
Patients (n=45) planned for knee arthroplasty by one specific orthopaedic surgeon were 
consecutively included, spinal anaesthesia was used in all cases. The included patients 
had an age range of 34 - 84 years and a BMI range of 19.6 – 43.0. The patients were 
randomised into three groups (n=15), and blinded to the patient, surgeon, anaesthetic 
and laboratory staff. Groups 1 and 3 receiving iNO 80 ppm or placebo throughout the 
entire operation, whereas group 2 received iNO 80 ppm in the beginning and in the end 
of the operation, thus with a break in iNO administration during the period of activated 
tourniquet (Fig. 7).  
An intravenous line, 18 or 20 gauge were inserted in the cubital fossa or in the forearm 
for blood sampling (BD Venflon™). Spinal anaesthesia was performed by an 
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anaesthesiologist not participating in the study. Thereafter, an oxygen mask, covering 
mouth and nose, with 5 liter/min oxygen (EcoOxygen Mask, Intersurgical Ltd, UK) 
mixed with NO or placebo was applied. Blood samples for methaemoglobin were taken 
hourly. Surgery, and therefore muscle biopsies were performed by the same 
orthopaedic surgeon in all patients. During the surgery the patients were modestly 
sedated with propofol (0.5-4.0 mg/kg BW/hour). 
 
TREATMENT STUDY IV 
NO (final blended at a concentration of 80 ppm NO in inspired gas, INOmax®, Ikaria®, 
Inc., Hampton, NJ, USA) or placebo (nitrogen, N2, Ikaria®, Inc.) was administered 
through the INOvent® delivery system (Datex-Ohmeda, Inc. Madison, USA). 
 
BLOOD SAMPLING AND MUSCLE BIOPSIES STUDY IV 
Blood samples were collected into standard EDTA tubes. Plasma was collected after 
centrifugation at 4,000 rpm for 10 min in +4◦C and then frozen at –80°C until 
subsequent analysis. Plasma levels of soluble ICAM-1, E-Selectin, P-Selectin and 
VCAM-1 were measured according to the manufacturer’s instructions using a 
multiplex ELISA kit, (R&D systems®, Abingdon, UK) designed for use with a 
Luminex® analyser. HMGB1 was analysed using ELISA (Shino-Test Corporation, 
Japan). Methaemoglobin, as a marker of exposed iNO, was taken and measured hourly 
with an ABL800 Flex blood gas instrument (Radiometer Medical, Brønshøj, Denmark). 
Muscle biopsies were immediately frozen in isopentane (C5H12) with liquid nitrogen 
(N) and stored at -80°C for subsequent analysis. Biopsies from seven patients in each 
Figure 7. Flow chart of the study design. iNO = inhaled nitric oxide, N2 = nitrogen (placebo). 
Group 2 has a break in NO administration during the period of activated tourniquet, 
administration of NO restarts approximately 2 minutes before the tourniquet release. 
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group were analysed using immunohistochemistry technique. These were selected from 
the patients with the best preserved histopathology of the pre-and post ischemic biopsy. 
The specimens were analysed regarding ICAM (intercellular adhesion molecule), 
VCAM (vascular adhesion molecule), P-selectin and CD68/macrophages. 
The protocols regarding the immunohistochemistry staining process are elaborately 
described in paper III. 
 
STATISTICAL ANALYSIS 
The results are presented as means and standard error of mean the (SEM) for study I-IV 
if not stated otherwise, ordinal data (VAS) in study I-II are presented as medians and 
interquartile range. In study I-IV longitudinal data was calculated using two-factor 
repeated-measures analysis of variance (ANOVA) with post hoc comparisons 
(Scheffe´) when applicable, using Statistica 5.5 for Windows. For cytokines in study II 
the area under the curve (AUC) was calculated, and thereafter, a mixed linear effects 
model was performed, which included sequence (if they had NO or placebo at the first 
or at the second occasion), to evaluate if tolerance effect existed. For some cytokines, 
the natural logarithm of AUC was calculated due to outliers and insufficient normal 
distribution. For the calculations in study II the software SPSS 15.0 was used. Because 
the VAS data are ordinal in study I and II, and the immunohistochemical data were 
nominal in study IV, the sign test was used. A P-value of 0.05 was considered to be 
indicating a significant difference. 
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RESULTS AND DISCUSSION  
This section will present the results as an overview and in brief put them in perspective. 
Detailed results are given in the separate papers.  
 
EFFECTS OF ENDOTOXIN AND TREATMENT (STUDY I-III) 
 
Clinical condition 
All participants felt varying degrees of the typical flu-like symptoms appearing within 
60-90 minutes lasting 3 to 4 hours after the endotoxin. No clinical difference between 
placebo/glucocorticoids (placebo/gc) and iNO/ glucocorticoids (iNO/gc) treatments 
was found. 
 
Body temperature, heart rate 
Body temperature and heart rate increased significantly following endotoxin challenge 
compared with baseline. However, no differences were seen between the two 




Figure 8. In study I (left) glucocorticoids (gc) 2 mg/kg were administrated and inhaled NO (30 
ppm, ●-●) or placebo (nitrogen, ○-○) initiated 30 minutes after endotoxin challenge (2 ng/kg). In 
study II (right) iNO (80 ppm, ●-●) or placebo (nitrogen, ○-○) was started two hours previous to 
endotoxin challenge (2 ng/kg) followed by gc 2 mg/kg 30 minutes later. The arrows indicate 
when endotoxin and treatment were given. HR (Heart rate), Temp (temperature). Mean ± 
SEM. # * P<0.05 compared with baseline for iNO/gc and placebo/gc respectively.  
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Haematological parameters  
In study II a significant increase in methaemoglobin levels compared with baseline for 
the iNO/gc treated was observed, as well as a significant difference over time in 
contrast to placebo/gc treated (Fig. 9). Since methaemoglobin is a redox-product of NO 
it may be used as marker of exogenously administered iNO (83). 
In both studies white blood cell count (WBC) increased significantly over time 
compared to baseline, platelet count (PC) decreased significantly in study I but not in 
study II, no difference regarding WBC or PC was observed between the two treatments 






Figure 9. Study II. Significant increase of methaemoglobin levels compared to baseline 
with the iNO/gc treatment (80 ppm ●-●, * P<0.05) and a difference compared with 
placebo/gc treatment (nitrogen ○-○, # P<0.05). Mean ± SEM. 
Table 1. Study I. iNO (inhaled nitric oxide), gc (glucocorticoid), WBC (white blood 
cell count x 109/L), PC (platelet count x 109/L), Hb (haemoglobin g/L). Mean ± SEM. 




In study I endotoxin challenge markedly elevated the plasma levels of TNF-α, IL-6, IL-
10, and IL-1ra concentrations versus baseline, but there was no difference between 
placebo/gc and iNO/gc treatment. sRAGE decreased significantly over time compared 
to baseline with placebo/gc treatment, whereas during iNO/gc treatment the levels were 
preserved (Fig. 10). 
In study II endotoxin administration elevated the plasma levels of all the measured 
Table 2. Study II. iNO (inhaled nitric oxide), gc (glucocorticoid), WBC (white blood cell 
count x 109/L), PC (platelet count x 109/L), Hb (haemoglobin g/L). Mean ± SEM. ∗ P<0.05 
when compared to baseline values. 
Figure 10. Study I. Cytokine response after endotoxin challenge (2 ng/kg) in healthy 
volunteers. Treatment with glucocorticoids (single injection, 2 mg/kg) and inhaled nitric 
oxide (30 ppm, ●-●) or placebo (nitrogen, ○-○) was started 30 minutes after the endotoxin, 
lasting during 5 hrs. Mean ± SEM.  
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cytokines with the exception of sRAGE, HMGB1 (Fig. 11) and IL-4 (not shown). As in 
study I no difference was observed between placebo/gc and iNO/gc treatment. 
Endotoxin elicited the expected clinical signs and activation of cytokine levels 
compared with previous endotoxin administration data in humans not treated with gc 
(40, 43), however, no significant difference was observed between the iNO/gc and the 
placebo/gc treated in any of the two studies. Nevertheless, it is not appropriate to 
compare the values of the cytokines in study I and II with each other. This is due to 
different types of analytic methods, electrochemiluminescence and ELISA (110). 
sRAGE was analysed with the same kind of ELISA kit but at a different occasion. 
 
The rational for study I-III is the anti-inflammatory properties of NO in combination 
with gc as reported by Da et al. Using the combination as a treatment after endotoxin 
challenge in a porcine model resulted in a blunted inflammatory response in systemic 
Figure 11. Cytokine response after endotoxin challenge (2 ng/kg) in healthy volunteers. 
Treatment with inhaled NO (80 p.p.m., ●-●) or placebo (nitrogen,○-○) was started 2 h 




organs (62). The hypothesis that an interaction between glucocorticoids and iNO could 
exist may have started from a Chinese study on patients with SARS (severe acute 
respiratory syndrome). When given a combination of glucocorticoid and iNO an 
improvement in oxygenation was seen as well as indications on regress in the disease 
per se, however, the study included only few patients thereby not allowing any 
conclusions (111). In study II we increased the iNO concentration from 30 to 80 ppm 
compared to study I, also, we started the inhalation 2 hours before instead of 30 
minutes after the endotoxin challenge. Still, no anti-inflammatory effect by the 
combined therapy, iNO/gc compared to placebo/gc, could be observed in the measured 
parameters.  
The timing of NO administration may be of relevance, since beneficial response was 
seen when NO was administered early in relation to late in experimental endotoxin 
ARDS-pig lungs (112) . A dose dependent relation between inhaled NO and systemic 
effects has been shown in animal (90, 91) and in human models of 
ischemia/reperfusion injury (93) as well as in an animal model of coronary patency 
after thrombolysis (113). Also, there is a known difference to equivalent stimulus such 
as endotoxin in different species (114, 115). Therefore, the discrepancies between doses 
used in animal models compared to human models are often thousand-fold, for 
example, pigs may receiving 80µg/kg endotoxin as an infusion for 6 hours (62). Also, 
animal experiments allow investigation on a cellular level in specific organs e.g. lung, 
liver and kidney (62).  
The method we used in study I-III, repetitive endotoxin challenge in a crossover 
fashion with the volunteers being their own controls, has been questioned due to 
tolerance effect. This means that the second endotoxin administration could generate a 
lower inflammatory response when using a washout period of two weeks (116). 
However, extending the washout period to 6 weeks has been shown to eliminate this 
tolerance effect (116, 117). 
 
Microparticles, study III 
Phalloidin is a peptide binding to filamentous actin which is only exposed on disrupted 
cells, thus, phalloidin binding may therefore indicate cell fragments otherwise detected 
as microparticles (MP) (118). In study III the percentage of particles positive for 
phalloidin was 10.6 ± 6.9% (mean ± SD), median 10%, indicating acceptable sample 
handling with low numbers of cell fragments in plasma samples (118) (Fig. 12). 
 
Figure 12. Percental phalloidin 
positive particles content in the 
included samples. Horizontal line 
indicating mean value. Reproduced 
with permission from Fariborz 
Mobarrez, Biomedical Scientist, PhD 
Student
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Since MPs have an overrepresentation of phosphatidylserine (PS) on the outer surface 
compared to ordinary cell membrane, lactadherin that binds to PS is used as a marker 
for all MP despite cell origin (Fig. 13).  
In study III all MPs, both total and cell-specific (CD42a - platelet specific and CD14 
– monocyte specific), increased significantly compared to baseline at 2.5 and 5.5 
hours after endotoxin with the exception of endothelial derived MP (CD144 – 
endothelial specific) that did not increase over time compared to baseline (Fig. 14). 
Platelet derived MP (PMP) positive to CD40L increased significantly after 2.5 hours 
and the same pattern could be seen for HMGB1 positive monocyte MP (MMP) where 
an early increase was seen after 5.5 hours. No differences were seen between the two 
treatments (iNO/gc and placebo/gc) regarding impact on MPs levels. 
The majority of the MPs in the blood stream emanate from platelets, as observed 
previously both in healthy humans and septic patients (119, 120).  
HMGB1 is secreted extracellulary by monocytes/macrophages in response to 
proinflammatory stimuli (e.g. LPS, TNFα and IL-1β) (15), but HMGB1 is also 
passively released from damaged/necrotic (13) and apoptotic cells (17). Hence, the 
release of HMGB1 and MPs shows important similarities and they both act as 
important mediators of immune responses (18). We found a significant increase in 
HMGB1 positive MMPs 5.5 hours after endotoxin challenge, indicating monocyte 
activation and/or apoptosis. To our knowledge, neither has an increase in HMGB1 
been described in a human endotoxin model before (117), nor has it been 
demonstrated that HMGB1 binds to MMPs. HMGB1 has been described as a late 
mediator of inflammation in mice (14). The elevation of HMGB1 seen in the current 
study is in line with that in trauma patients, where a peak was seen 2 - 6 hours after 
hospital admittance (121). HMGB1 may be bound to PS exposed on MMPs since 
Rouhiainen et al have shown that HMGB1 bind directly to PS exposed on platelets 
Figure 13. Microparticles incubated with different antibodies. Reproduced with 
permission from Fariborz Mobarrez, Biomedical Scientist, PhD Student. 
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(122). We identified only MPs expressing PS, meaning that all MPs measured with 
our flow cytometry assay have PS molecules on their surface and we found HMGB1 
to be elevated in MMPs. However, HMGB1 could also be exposed on MPs other than 
MMPs since most cells have HMGB-1 present in the nucleus (12). In study II soluble 
HMGB1 were measured with a commercially available ELISA, although at different 
time points (1.5 3.5 and 24 hours after endotoxin administration). The lack of 
alteration of HMGB1 in study II and III may be due to different sensitivities of the 
assays (ELISA vs flow cytometry), but it is also possible that the peak occurring at 
5.5 hours after endotoxin administration, was missed at the 3.5 hour sampling.  
Figure 14. Microparticles after endotoxin challenge in healthy volunteers. 
Endotoxin was administered at -0.5 hours and glucocorticoids (gc) at 0 hours. 
Treatment in a double-blind randomized, crossover fashion regarding inhaled NO 
or inhaled placebo (nitrogen, N2). Mean ± SEM.
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The endotoxin challenge resulted also in CD40L expression on PMPs, to our 
knowledge an observation not earlier described. This molecule (CD40L, CD40 ligand 
or CD154), originally found on stimulated T-cells, are also expressed on platelets 
(123). Interaction between CD40L and the receptor CD40 cause both pro-
inflammatory and pro-thrombotic activities including the induction of endothelial 
cells secreting chemokines and expressing adhesion molecules (123-125). 
Furthermore, CD40L stimulate expression of tissue factor in endothelial cells (126) 
and reduction of CD40L on platelets as well as in its soluble form is associated with a 
reduced thrombin generation (124). Thus, an increase in the number of PMPs and 
increased PMPs exposing CD40L is likely to reflect platelet activation (124). 
The increase in CD14+ monocyte MPs are in consistence with the findings by Aras et 
al in healthy volunteers receiving endotoxin, where a return to normal levels was 
observed within 8 hours (127). In contrast to platelet and monocyte MPs, endothelial 
MPs measured with CD144 (VE-Cadherin) were not found to be elevated. Aras et al 
found elevation in CD144 positive EMPs in 3 out of 18 healthy volunteers receiving 
endotoxin, a finding which we interpret as similar to ours, i.e. no significant effect 
(127). In studies on sepsis patients EMPs have been shown to lead to various results, 
an observation that may depend on the use of different antibodies (119, 128). The use 
of CD144 in our study may be a limitation, since this molecule may provide limited 
sensitivity to detect EMPs. The combination with other antibodies may increase the 
sensitivity to detect endothelial cell activation (129). Another reason for the disparity 
between different studies regarding levels of EMPs, may relate to when the samples 
were taken in relation to the course of the septicemia. The human endotoxin model 
makes it possible for us to study the whole time-pattern of the inflammatory response 
compared to septic patients, where the beginning of the course of the disease often 
already has occurred when the patients are admitted to the hospital.  
 
STUDY IV 
Endothelial cell activation and inflammation in this study was evaluated using two 
standard methods, ELISA and immunohistochemical techniques. Plasma levels of 
HMGB1, P-selectin, VCAM, and E-selectin all remained unaltered with no differences 
between groups. However, soluble ICAM showed a small, but significant, decrease in 
group 1 and 3 (Fig. 15). 
In addition, when analysing the muscle biopsies regarding the expression of adhesion 
molecules (ICAM, VCAM, P-selectin) and CD68/macrophages, no differences were 
observed between the three groups or within the separate groups before and after 
ischemia. 
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As in study II methaemoglobin increased significantly over time in the iNO treated 
groups compared to the placebo treated, thus, serving as a marker of exposure to iNO 
(83) (Fig. 16). 
Surprisingly, no signs of endothelial cell activation or an inflammatory response could 
be observed neither in plasma nor in muscle biopsies in this clinical human study with 
reperfusion following an ischemic event. As a consequence, no influence was seen nor 
could be expected, regarding the randomised iNO exposure on the measured 
parameters. Our result are in contrast to Mathru et al who found, in anaesthetised 
patients going through knee surgery, significantly increased inflammatory parameters 
in blood and muscle that were attenuated by the administration of iNO (93). Although 
Figure 15. Effects on soluble adhesion molecules and HMGB1 in plasma from patients. A 
significant decrease in ICAM was observed in group 1 (iNO) at time-point 3 (two hours after 
tourniquet release) and in group 3 (placebo) at time point 2 (at the end of operation) and 3. No 
differences were observed between the groups. * P<0.05 compared with baseline. Mean ± 
SEM. 
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total tourniquet duration in the present study was 60-140 minutes, which is in 
concordance with the approximately two hours presented by Mathru et al, some 
differences between our and Mathru´s study may be pointed out (93). Firstly, in the 
present study the patients all had spinal anaesthesia with propofol sedation in 
concordance to the clinical routine, in contrast to Mathru et al who used general 
anaesthesia with thiopental and isoflurane. The choice of anaesthetic method may have 
importance, since different anaesthetic drugs have been reported to have influence on 
inflammation in various settings. For example, isoflurane anaesthesia has been found to 
impair renal function in an ovine endotoxin study (130), isoflurane has also been 
demonstrated to protect the hepatic tissue compared to penthobarbital sodium in an rat 
I/R model (131), whereas isoflurane did not attenuate the liver damage ketamine did in 
an endotoxin rat model (132). Also, propofol has in the I/R setting been proposed to 
possess antioxidant capabilities, both in rats (133) and in humans (134-137). However, 
lack of beneficial effects against myocardial I/R injury (rat) using propofol has also 
been reported (138). Further, in patients undergoing coronary artery bypass graft 
surgery having remote ischemic precondition, propofol anaesthesia could not, 
compared to isoflurane decrease myocardial damage (139). Hence, there are several 
inconsistencies regarding the effect on inflammation by different anaesthetic methods 
in the inflammatory setting. Since we used propofol sedation in addition to the spinal 
anaesthesia it could be speculated that this combination may have influenced the 
inflammatory response in the ischemic tissue. 
Secondly, our patients were almost twice as old compared to patients in the Mathru 
Figure 16. There was a significant increase in methaemoglobin levels compared with 
baseline for the iNO treated patients as well as a significant difference over time in contrast 
to the placebo treated (* P<0.05), also, a significant difference between the two iNO 
groups was observed (# P<0.05). Group 1 (iNO) and 3 (placebo, N2) receiving iNO 80 ppm 
or placebo throughout the entire operation, whereas group 2 (piNO) only received iNO 80 
ppm in the beginning and in the end of the operation. Time-point 1; before the spinal 
anesthesia, time-point 2; before tourniquet activation, time-point 3; after tourniquet release. 
Mean ± SEM.  
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study (93). A positive correlation between age and the plasma concentration of soluble 
ICAM and VCAM has been observed in humans (140). Also, in rats the expression of 
soluble adhesion molecules has been reported to increase during aging, and when 
treated with LPS a more pronounced expression was seen in older animals (141). 
Therefore, it seems unlikely that the higher age in the present study could explain the 
difference in the inflammatory response. 
 
HMGB1 has been shown to be of vital importance in mediating injury in settings of 
I/R, for example, in mice HMGB1 protein expression in the liver was up-regulated one 
hour after reperfusion, and after 30 minutes in the heart (21, 23). In patient studies with 
cerebral and myocardial ischemia respectively, elevated levels of HMGB1 were seen 
within 24 hours (24, 25). The levels of HMGB1 in the present study are in the expected 
normal range (117, 142). 
A decrease in soluble ICAM was observed over time in the placebo group and in the 
group receiving iNO throughout surgery, a finding corresponding with an earlier study 
by Huda et al (143), where a decrease in soluble ICAM was seen post-tourniquet in 
patients undergoing knee surgery. Notably this was seen in conjunction with an 
increase in ICAM mRNA in muscle biopsies (143). In our study the ICAM staining in 
the muscle biopsies does not confirm this decrease in soluble ICAM. Followingly, we 
do not interpret these small changes as clinically relevant. 
 
In this study we administrated a maximal dose of iNO in order to evaluate the 
hypothesised anti-inflammatory effect, throughout the whole period of surgery or with 
a break when the tourniquet was activated. This design was used in order to investigate 
if iNO administered when there was circulation to the leg could modulate the 
inflammatory response, hypothesising that the administration of iNO may create a 
repository of NO (87, 88). 
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CONCLUSIONS 
Based on the experiments performed in this thesis the following conclusions were 
made: 
 
• In the human model of volunteers receiving 2 ng/kg endotoxin, the clinical 
symptoms and increased cytokine activation in plasma are in agreement with 
current knowledge. 
 
• In this human endotoxemia model, the combination of intravenously 
administered glucocorticoids and inhaled nitric oxide, using a low dose (30 
ppm) and a maximal dose (80 ppm), elicited no anti-inflammatory effects with 
regard to; 
 
1. Clinical symptoms 
 
2. Cytokines in plasma 
 
3. Microparticles in plasma 
 
• The endotoxin infusion in healthy volunteers resulted in an increase in 
microparticles released from platelets and from monocytes but not from the 
endothelium.  
 
• The endotoxemia generated an early increase of the activation markers 
HMGB1 on monocyte microparticles and CD40L on platelet microparticles. 
 
 
• In patients undergoing knee arthroplasty in spinal anesthesia, the 
ischemia/reperfusion created by a tourniquet did not cause any signs of 
endothelial cell activation or inflammatory response measured as levels of 
adhesion molecules and macrophages in muscle biopsies as well as HMGB1 
and soluble adhesion molecules in plasma. Hence, no influence was seen nor 
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